Edition:
United States

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

125.20SEK
22 Mar 2017
Change (% chg)

-- (--)
Prev Close
125.20kr
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
950,069
52-wk High
128.80kr
52-wk Low
89.50kr

SOBIV.ST

Chart for SOBIV.ST

About

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers... (more)

Overall

Beta: 1.38
Market Cap(Mil.): kr33,798.72
Shares Outstanding(Mil.): 270.39
Dividend: --
Yield (%): --

Financials

  SOBIV.ST Industry Sector
P/E (TTM): 41.63 29.30 30.07
EPS (TTM): 3.00 -- --
ROI: 10.65 13.52 13.05
ROE: 16.16 14.43 14.20

BRIEF-Sobi CEO sees broad interest in Partner Products platform

Feb 16 Swedish Orphan Biovitrum AB CEO Geoffrey McDonough to reporters:

Feb 16 2017

BRIEF-Sobi says expands haemophilia B development portfolio

* Sobi expands haemophilia B development portfolio by adding rFIXFc-XTEN to its collaboration agreement with Bioverativ Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

Feb 16 2017

BRIEF-Sobi Q4 EBITA lags expectations

* Q4 total revenue of sek 1,292 m (814), an increase of 59 per cent (54 per cent at cer)

Feb 16 2017

Drug maker Sobi eyes sale of Partner Products unit

STOCKHOLM Swedish drug maker Swedish Orphan Biovitrum (Sobi) said on Friday it was in talks with a private equity firm regarding a possible sale of its Partner Products business area.

Feb 03 2017

Drug maker Sobi eyes sale of Partner Products unit

STOCKHOLM, Feb 3 Swedish drug maker Swedish Orphan Biovitrum (Sobi) said on Friday it was in talks with a private equity firm regarding a possible sale of its Partner Products business area.

Feb 03 2017

BRIEF-Sobi confirms divestment discussions, shares halted

* Says confirms that company is in discussions with a private equity firm regarding a possible sale of its partner products business area excluding Kineret and Orfadin.

Feb 03 2017

UPDATE 1-Sobi Q3 EBITA beats expectations by 54 pct, raises outlook

* Reuters poll: Sobi Q3 ebita was seen at sek 183 million, revenues at 1,139 million

Oct 27 2016

BRIEF-Sobi Q3 EBITA tops forecasts, raises outlook

* Reuters poll: Sobi Q3 ebita was seen at sek 183 million, revenues at 1,139 million

Oct 27 2016

BRIEF-Sobi says EU grants SOBI003 orphan designation

* Says EU commission gives SOBI003 orphan drug status for treatment of MPS IIIA Further company coverage: (Reporting by Stockholm Newsroom)

Oct 19 2016

BRIEF-Sobi appoints Milan Zdravkovic as new head of R&D

* Milan Zdravkovic joins Sobi as Senior Vice President, Head of Research & Development

Sep 26 2016

More From Around the Web

Earnings vs. Estimates